EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics

Alexander M Curreri, Jayoung Kim, Michael Dunne, Pavimol Angsantikul, Morgan Goetz, Yongsheng Gao, Samir Mitragotri iD

Advanced Science · 2023-03 · 10 (7)

DOI: 10.1002/advs.202205389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.01.2023. Verfasst von Alexander M Curreri und 6 weiteren Autor:innen. Beteiligte Einrichtung: John A. Paulson School of Engineering and Applied Sciences, Harvard University, 150 Western Ave, Allston, MA, 02134, USA. Hauptthemen laut MEDLINE: Deep Eutectic Solvents, Biological Products. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteins are among the most common therapeutics for the treatment of diabetes, autoimmune diseases, cancer, and metabolic diseases, among others. Despite their common use, current protein therapies, most of which are injectables, have several limitations. Large proteins such as monoclonal antibodies (mAbs) suffer from poor absorption after subcutaneous injections, thus forcing their administration by intravenous injections. Even small proteins such as insulin suffer from slow pharmacokinetics which poses limitations in effective management of diabetes. Here, a deep eutectic‐based delivery strategy is used to offer a generalized approach for improving protein absorption after subcutaneous injections. The lead formulation enhances absorption of mAbs after subcutaneous injections by ≈200%. The same composition also improves systemic absorption of subcutaneously injected insulin faster than Humalog, the current gold‐standard of rapid acting insulin. Mechanistic studies reveal that the beneficial effect of deep eutectics on subcutaneous absorption is mediated by their ability to reduce the interactions of proteins with the subcutaneous matrix, especially collagen. Studies also confirm that these deep eutectics are safe for subcutaneous injections. Deep eutectic‐based formulations described here open new possibilities for subcutaneous injections of therapeutic proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep Eutectic SolventsBiological ProductsHumansAntibodies, MonoclonalDiabetes MellitusInjections, SubcutaneousInsulin

Stichwörter der Autor:innen

bioavailabilitybiologicsdeep eutectic solventsionic liquidsmonoclonal antibodiespharmacokineticssubcutaneous

Substanzen

Antibodies, MonoclonalDeep Eutectic SolventsInsulinBiological Products

Autor:innen und Institutionen

  • John A. Paulson School of Engineering and Applied Sciences, Harvard University, 150 Western Ave, Allston, MA, 02134, USA.
  • Wyss Institute for Biologically Inspired Engineering at Harvard University, 3 Blackfan St, Boston, MA, 02115, USA.

ORCID-Profile: Samir Mitragotri

Zitieren

APA

Curreri, A. M., Kim, J., Dunne, M., Angsantikul, P., Goetz, M., Gao, Y., & Mitragotri, S. (2023). Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics. Advanced Science, 10(7). https://doi.org/10.1002/advs.202205389

Vancouver

Curreri AM, Kim J, Dunne M, Angsantikul P, Goetz M, Gao Y, et al. Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics. Advanced Science. 2023;10(7). doi:10.1002/advs.202205389

BibTeX
@article{Curreri2023,
  author = {Curreri, Alexander M and Kim, Jayoung and Dunne, Michael and Angsantikul, Pavimol and Goetz, Morgan and Gao, Yongsheng and Mitragotri, Samir},
  title = {Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics},
  journal = {Advanced Science},
  year = {2023},
  volume = {10},
  number = {7},
  doi = {10.1002/advs.202205389}
}
Kostenlos starten →